Inhibrx Stock Buy Hold or Sell Recommendation
| INBX Stock | USD 14.86 0.78 5.54% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Inhibrx is 'Strong Sell'. A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Inhibrx given historical horizon and risk tolerance towards Inhibrx. When Macroaxis issues a 'buy' or 'sell' recommendation for Inhibrx, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Inhibrx Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Inhibrx Stock please use our How to Invest in Inhibrx guide. In addition, we conduct extensive research on individual companies such as Inhibrx and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Inhibrx. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.
Inhibrx |
Execute Inhibrx Buy or Sell Advice
The Inhibrx recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Inhibrx. Macroaxis does not own or have any residual interests in Inhibrx or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Inhibrx's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Excited | Details | |
Analyst Consensus | Strong Sell | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Inhibrx Trading Alerts and Improvement Suggestions
| Inhibrx had very high historical volatility over the last 90 days | |
| Inhibrx has a very high chance of going through financial distress in the upcoming years | |
| Inhibrx was previously known as INXB Old and was traded on NASDAQ Exchange under the symbol INXB. | |
| The company reported the previous year's revenue of 1.8 M. Net Loss for the year was (241.36 M) with loss before overhead, payroll, taxes, and interest of (107.99 M). | |
| Inhibrx currently holds about 176.38 M in cash with (193.31 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.52. | |
| Inhibrx has a frail financial position based on the latest SEC disclosures | |
| Roughly 67.0% of the company shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Acquisition by Kayyem Jon Faiz of 34843 shares of Inhibrx at 14.2269 subject to Rule 16b-3 |
Inhibrx current analysts advice
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Inhibrx analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Inhibrx analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
The consensus estimates and target price estimation comprises individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.
Inhibrx Returns Distribution Density
The distribution of Inhibrx's historical returns is an attempt to chart the uncertainty of Inhibrx's future price movements. The chart of the probability distribution of Inhibrx daily returns describes the distribution of returns around its average expected value. We use Inhibrx price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Inhibrx returns is essential to provide solid investment advice for Inhibrx.
| Mean Return | 0.17 | Value At Risk | -6.11 | Potential Upside | 4.92 | Standard Deviation | 3.16 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Inhibrx historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Inhibrx Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as Inhibrx, soars without any apparent reason? This usually happens because many institutional investors are aggressively trading Inhibrx back and forth among themselves.
| Shares | Manufacturers Life Insurance Co | 2024-06-30 | 0.0 | Metlife Inc | 2024-06-30 | 0.0 | Hhg Plc | 2024-06-30 | 0.0 | Simplex Trading, Llc | 2024-06-30 | 0.0 | State Of Wisconsin Investment Board | 2024-06-30 | 0.0 | Citadel Advisors Llc | 2024-06-30 | 0.0 | Profund Advisors Llc | 2024-06-30 | 0.0 | Yakira Capital Management, Inc. | 2024-06-30 | 0.0 | Cnh Partners, Llc | 2024-06-30 | 0.0 | Dekabank Deutsche Girozentrale | 2024-06-30 | 26.4 K | Advisor Group Holdings, Inc. | 2024-06-30 | 6.7 K |
Inhibrx Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 9.4M | 117.1M | 2.6M | 142.6M | 4.1M | 3.9M | |
| Net Borrowings | 33.8M | 41.4M | 40.0M | 128.9M | 148.2M | 155.6M | |
| Free Cash Flow | (33.9M) | (49.3M) | (81.2M) | (116.0M) | (197.9M) | (188.0M) | |
| Depreciation | 1.2M | 1.0M | 1.2M | 1.2M | 1.2M | 979.1K | |
| Other Non Cash Items | 9.6M | 11.6M | 2.7M | 5.1M | 6.7M | 4.6M | |
| Capital Expenditures | 1.8M | 1.4M | 864K | 686K | 4.6M | 4.8M | |
| Net Income | (51.4M) | (76.1M) | (81.8M) | (145.2M) | (241.4M) | (229.3M) | |
| End Period Cash Flow | 11.5M | 128.7M | 131.3M | 273.9M | 277.9M | 291.8M | |
| Change To Netincome | 6.4M | 4.3M | 16.5M | 20.5M | 23.5M | 24.7M | |
| Change To Inventory | (672K) | (2.5M) | 7.8M | (11.0M) | (9.9M) | (9.4M) | |
| Investments | (1.8M) | (1.4M) | (809K) | (686K) | (4.6M) | (4.4M) |
Inhibrx Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Inhibrx or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Inhibrx's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Inhibrx stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.08 | |
β | Beta against Dow Jones | 0.64 | |
σ | Overall volatility | 3.14 | |
Ir | Information ratio | 0.01 |
Inhibrx Volatility Alert
Inhibrx currently demonstrates below-average downside deviation. It has Information Ratio of 0.01 and Jensen Alpha of 0.08. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Inhibrx's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Inhibrx's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Inhibrx Fundamentals Vs Peers
Comparing Inhibrx's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Inhibrx's direct or indirect competition across all of the common fundamentals between Inhibrx and the related equities. This way, we can detect undervalued stocks with similar characteristics as Inhibrx or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Inhibrx's fundamental indicators could also be used in its relative valuation, which is a method of valuing Inhibrx by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Inhibrx to competition |
| Fundamentals | Inhibrx | Peer Average |
| Return On Equity | -20.31 | -0.31 |
| Return On Asset | -0.57 | -0.14 |
| Profit Margin | 1,020 % | (1.27) % |
| Current Valuation | 9.32 M | 16.62 B |
| Shares Outstanding | 14.48 M | 571.82 M |
| Shares Owned By Insiders | 23.54 % | 10.09 % |
| Shares Owned By Institutions | 67.49 % | 39.21 % |
| Number Of Shares Shorted | 976.67 K | 4.71 M |
| Price To Book | 1.14 X | 9.51 X |
| Price To Sales | 120.82 X | 11.42 X |
| Revenue | 1.8 M | 9.43 B |
| Gross Profit | (107.99 M) | 27.38 B |
| EBITDA | (206.69 M) | 3.9 B |
| Net Income | (241.36 M) | 570.98 M |
| Cash And Equivalents | 176.38 M | 2.7 B |
| Cash Per Share | 4.52 X | 5.01 X |
| Total Debt | 210.14 M | 5.32 B |
| Debt To Equity | 4.22 % | 48.70 % |
| Current Ratio | 7.51 X | 2.16 X |
| Book Value Per Share | 15.15 X | 1.93 K |
| Cash Flow From Operations | (193.31 M) | 971.22 M |
| Short Ratio | 14.06 X | 4.00 X |
| Earnings Per Share | 119.39 X | 3.12 X |
| Target Price | 15.0 | |
| Number Of Employees | 166 | 18.84 K |
| Beta | 2.88 | -0.15 |
| Market Capitalization | 203.82 M | 19.03 B |
| Total Asset | 307.89 M | 29.47 B |
| Retained Earnings | (613.73 M) | 9.33 B |
| Working Capital | 239.05 M | 1.48 B |
| Net Asset | 307.89 M |
Note: Acquisition by Kayyem Jon Faiz of 18750 shares of Inhibrx at 14.1921 subject to Rule 16b-3 [view details]
Inhibrx Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Inhibrx . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Inhibrx Buy or Sell Advice
When is the right time to buy or sell Inhibrx? Buying financial instruments such as Inhibrx Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Inhibrx in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Information Technology ETFs Thematic Idea Now
Information Technology ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Information Technology ETFs theme has 50 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Information Technology ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Inhibrx Stock Analysis
When running Inhibrx's price analysis, check to measure Inhibrx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibrx is operating at the current time. Most of Inhibrx's value examination focuses on studying past and present price action to predict the probability of Inhibrx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibrx's price. Additionally, you may evaluate how the addition of Inhibrx to your portfolios can decrease your overall portfolio volatility.